T. N. Barsheskaya L. P. / G. D. Roberts S. A. / J. M. Co / Lilly / HIV PR / I. B. Duncan S. A. / H. L. Bryan S. A. / Agouron / Dupont / Merck / Vertex / Hyland / Abbott Laboratories / /
Country
United States / /
Currency
pence / /
Event
FDA Phase / Debt Financing / /
Facility
Skaggs Institute / D. Hall / National Cancer Institute / The Scripps Research Institute / /
IndustryTerm
active site / chemical synthesis / natural product / substrate-binding site / hydrolysis products / aspartic / polymerase active site / transpeptidation product / side chain / hydrophobic binding site / energy / enzyme active site / amine product / ultimate solution / aspartate groups / cleavage site / chemical mechanism / AIDS therapy / hydroxy / enzyme-binding site / rst / treatment of AIDS / side chains / carbonyl / rate-limiting chemical step / /
MedicalCondition
HIV / epidemic / infectious virions / AIDS epidemic / acquired immunodeficiency syndrome / epidemic proportions / virus infection / AIDS / infection / /
National Cancer Institute / National Institute of Health / Israel Science Foundation / Royal Society of Chemistry / Department of Chemistry / Skaggs Institute for Chemical Biology / Scripps Research Institute / FDA / UNAIDS / Stanford / US Center for Diseases Control / /
Person
A. Nguyen / V / Garrett M. Morris / Ashraf Brik / S. J. Stahl / K. Mohan Rao / H. Schmidt / V / O. Park / V / M. V. Toth / Nat / S. Kim / H. Yoon / S. C. Kim / L. Clawsen / T. Lee / V / Carr / V / M. L. Moore / V / M. L. Moore / D. L. Beveridge / Jr. / C. S. Lee / H. Choi / R. A. Kramer / J. H. Ok / Chi-Huey Wong / T. A. Tomaszek / Jr. / Turk / W. E. Harte / C. T. Baker / /
Position
model substrate / RT / General / messenger / Representative structure / model for drug resistance / G. R. Marshal / /